Chang W. Choi
Seoul, 139706, Republic of Korea
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 39 publications
Cutoff SUVR of [18F]Florapronol PET for Differentiating Alzheimer's Dementia from Normal Controls: Insights from ROC Analysis and Partial Volume Correction.
Journal: Nuclear medicine and molecular imaging
Published: November 20, 2024
F-18 FDG PET/CT Clinical Service Trends in Korea from 2018 to 2022: A National Surveillance Study.
Journal: Nuclear medicine and molecular imaging
Published: October 18, 2024
Evaluating 64 Cu-DOTA-rituximab as a PET agent in patients with B-cell lymphoma: a head-to-head comparison with 18 F-fluorodeoxyglucose PET/computed tomography.
Journal: Nuclear medicine communications
Published: August 19, 2024
A Phase II Study of 131I-rituximab for Patients With Relapsed or Refractory Marginal Zone Lymphoma.
Journal: Clinical Medicine Insights. Oncology
Published: August 30, 2023
Radioimmunotherapy with 131 I-rituximab for patients with relapsed or refractory follicular or mantle cell lymphoma.
Journal: Asia-Pacific journal of clinical oncology
Published: November 02, 2022
The role of 18F-FDG PET/CT in patients with diffuse large B-cell lymphoma after radioimmunotherapy using 131I-rituximab as consolidation therapy.
Journal: PloS one
Published: May 16, 2022
The Prediction of HER2-Targeted Treatment Response Using 64Cu-Tetra-Azacyclododecanetetra-Acetic Acid (DOTA)-Trastuzumab PET/CT in Metastatic Breast Cancer: A Case Report.
Journal: Journal of breast cancer
Published: October 12, 2021
A Phase 0 Microdosing PET/CT Study Using O-[18F]Fluoromethyl-d-Tyrosine in Normal Human Brain and Brain Tumor.
Journal: Clinical nuclear medicine
Published: May 25, 2021
The Feasibility of 64Cu-PSMA I&T PET for Prostate Cancer.
Journal: Cancer biotherapy & radiopharmaceuticals
Published: January 12, 2021
A preliminary clinical trial to evaluate 64Cu-NOTA-Trastuzumab as a positron emission tomography imaging agent in patients with breast cancer.
Journal: EJNMMI research
Published: July 27, 2020
A microdose clinical trial to evaluate [18F]Florastamin as a positron emission tomography imaging agent in patients with prostate cancer.
Journal: European journal of nuclear medicine and molecular imaging
Published: April 10, 2020
Last Updated: 09/26/2026